GENMAB (GE9 BE) stock market data APIs
€236.734
8.91(3.8%)
as of September 12, 2025
Try our APIs with
free plan!
GENMAB Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for GE9.BE.
Prev. Close
236.734
Open
245.6474
High
241.9251
Low
236.734
52 wk Range
155.8-244.9
Market Cap
22 148 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get GENMAB data using free add-ons & libraries
Get GENMAB Fundamental Data
GENMAB Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GENMAB News
New
Genmab A/S (GMAB) Scores FDA Breakthrough for Rina-S
In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. Genmab A/S stands fifth among them. Genmab A/S (NASDAQ:GMAB) is strengthening its position as a glob...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Genmab A/S Company Announcement COPENHAGEN, Denmark; September 9, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regul...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Genmab A/S Company Announcement COPENHAGEN, Denmark; September 09, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 47,532 shares as a consequence of the exercise of employee wa...
Genmab (CPSE:GMAB): Valuation Insights Following Breakthrough FDA Nod and Pipeline Progress
When Genmab (CPSE:GMAB) announced that its investigational antibody-drug conjugate, rinatabart sesutecan, received Breakthrough Therapy Designation from the U.S. FDA for a difficult-to-treat form of e...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
